In Brief ABCF1 has been associated with immune signaling and various autoimmune disorders. Arora and colleagues demonstrate that ABCF1 is an E2 ubiquitin-conjugating enzyme that regulates various innate immune responses in macrophages, including potentiation of TLR4 endocytosis and M2 polarization, and promotes endotoxin tolerance and survival during septic toxic shock.
INTRODUCTION
Sepsis is a bi-phasic disease characterized by an initial hyperinflammatory phase called systemic inflammatory response syndrome (SIRS), which is followed by an immune compromised phase called endotoxin tolerance (ET) (Biswas and Lopez-Collazo, 2009 ). The SIRS phase is marked by the drastic production of pro-inflammatory cytokines and downregulation of anti-inflammatory cytokines, whereas the opposite occurs during the ET phase (Cavaillon and Adib-Conquy, 2006) . In SIRS, the inflammatory insult leads to impaired blood vessel contractility and reduced cardiac index, resulting in circulatory failure (Ren and Wu, 2006) . Persistent circulatory failure leads to rupturing of the microcirculatory vasculature, a major determinant of mortality in sepsis (Levi et al., 2010) . A recent study reveals a protective role for interferon regulatory factor 3 (IRF3)-dependent IFN-b production in lethal LPS endotoxin-mediated sepsis by controlling the expression of silent information regulator transcript-1 (SIRT1) in murine bone-marrow-derived macrophages (BMDMs) (Yoo et al., 2014) . Previous studies also highlight the importance of macrophage polarization (Biswas and Lopez-Collazo, 2009 ) and ubiquitin-proteasome pathways (Wray et al., 2003) during sepsis, but the molecular mechanisms underlying these processes and the regulation of the switch from SIRS to ET requires more investigation.
Ubiquitin modification and its role in the crosstalk between proteins has been studied for the past few decades, but its role in immune response signaling is rather recent. The role of ubiquitin modification in activating or repressing protein function has recently been reported during TLR signaling mediated by the nuclear factor kB (NF-kB) and interferon type 1 (IFN-I) pathways (Heaton et al., 2016) , but its regulation remains uncharacterized. Downstream signaling from TLRs is mediated by either the MyD88-TIRAP or TRIF-TRAM pathway. Among all the TLRs, only LPS-activated TLR4 can induce both MyD88-and TRIFdependent signaling (Kagan et al., 2008) . It does this by mediating MyD88-dependent responses from the cell surface and TRIF-dependent responses when internalized into endosomes (Tanimura et al., 2008) . Recent research has uncovered a possible role for the polyubiquitination of cellular inhibitor of apoptosis 1/ 2 (cIAP1/2) and TNF receptor associated factor 3 and 6 (TRAF3 and TRAF6) (Tseng et al., 2010) in mediating the shift from MyD88-to TRIF-dependent signaling and subsequent IFN-I production in BMDMs. Studies have also shown that endocytosis of TLR4 in BMDMs is critically dependent on the phosphorylation of spleen tyrosine kinase (SYK) and phospholipase C gamma 2 (PLCg2) (Zanoni et al., 2011) . How these proteins 
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regulate TLR4 endocytosis during the shift between these two pathways still remains elusive.
Prior research has identified the upregulation of ABCF1, in TNF-a-stimulated synoviocytes from rheumatoid arthritis patients (Richard et al., 1998) . While retaining its ATP-binding cassette, ABCF1 is unusual as it lacks a transmembrane domain and does not function as a transporter. ABCF1 is thought to aid in translation initiation and is located in the cytoplasm and nucleoplasm (Paytubi et al., 2008) . Immunological studies have shown that ABCF1 is also involved in innate immune cytosolic DNA sensing mechanisms (Lee et al., 2013) and has been linked to susceptibility for autoimmune pancreatitis (Ota et al., 2007) . Due to the embryonic lethality of ABCF1-deficient mice (Abcf1 À/À ), we created an ABCF1 heterozygous mouse (Het;
) and studied its promoter activity during embryonic development and in various adult tissues . However, despite these studies, the molecular functions and physiological role of ABCF1 remains elusive.
Here, we report that ABCF1 is an E2 ubiquitin-conjugating enzyme that interacts with and mediates the polyubiquitination of key elements of the TLR4 signaling pathway. We demonstrate that ABCF1 controls the molecular switch that regulates LPSinduced TLR4 endocytosis and the concomitant transition from MyD88-to TRIF-dependent signaling, thereby regulating LPSinduced macrophage polarization and facilitating the SIRS-to-ET transition during sepsis. Overall, in a murine model of sepsis, ABCF1 is required for the production of IFN-I and SIRT1 and protects against lethality.
RESULTS

ABCF1
Mediates Macrophage Polarization to the M2 Phenotype after LPS Stimulation Our studies indicated that ABCF1 negatively regulates MyD88-dependent pro-inflammatory cytokine production upon activation of TLR2 (Peptidoglycan) and TLR9 (CpG DNA) signaling and positively regulates TRIF-dependent anti-inflammatory cytokine and IFN-b production upon activation of TLR3 (Poly I:C) signaling in BMDMs ( Figure S1A ). Therefore, to investigate whether ABCF1 also plays a role in both early and late phase TLR4 signaling and macrophage polarization, we first assessed the expression of M1 and M2 associated cell surface markers. Expression of M1 markers like CD86 and MHC-II were elevated in LPS and Abcf1 siRNA-treated cells, when compared with their respective scrambled controls ( Figure 1A) . Meanwhile, the M2-specific marker, CD206, was found to be expressed marginally less in LPS and Abcf1 siRNA-treated cells, compared to their respective controls.
Next, we examined whether siRNA silencing of ABCF1 expression in BMDMs would alter the activation status of transcription factors NF-kB (MyD88-dependent) and IRF3 (TRIF-dependent). Elevated expression of p-NF-kB p65 was observed in the nuclear extracts of Abcf1 siRNA-treated cells, both in the presence and absence of LPS ( Figure S1B ), when compared to their respective controls. By contrast, a reduction in IRF3 dimerization ( Figure 1C ) and phosphorylation ( Figure S1B ) was observed, regardless of LPS stimulation.
Since macrophage polarization has been tightly linked to the differential expression of various cytokines, we sought to determine whether siRNA silencing of ABCF1 also influences cytokine secretion in BMDMs. Upon treatment of BMDMs with Abcf1 siRNA alone, we observed a 20-to 40-fold increase in the secretion of M1-associated pro-inflammatory cytokines ( Figure 1B , S2), implying that loss of ABCF1 phenocopies the MyD88-dependent pro-inflammatory signaling. After 30 min of LPS stimulation, Abcf1 siRNA-treated BMDMs secreted 30-to 40-fold more of these pro-inflammatory cytokines than LPS treated scrambled controls. Whereas, the decreased expression of M2-associated anti-inflammatory cytokines was observed in Abcf1 siRNA-treated BMDMs, both with and without LPS stimulation ( Figures 1B, S2 ).
Previous studies have suggested that LPS induction of macrophages also lead to upregulation of hypoxia-inducible factor 1 alpha (HIF-1a) in a MyD88-dependent manner (Jantsch et al., 2011) . HIF-1a expression thereby positively regulates MyD88-dependent pro-inflammatory production, M1 macrophage polarization (Nakayama et al., 2013) and triggers renal hypoxia in SIRS phase of sepsis (Heyman et al., 2012) . Upon induction of hypoxia, decreased ABCF1 and increased HIF-1a expression were observed in BMDMs ( Figure 1D ) suggesting that loss of ABCF1 is modulated by MyD88-dependent hypoxia. Conversely, immunoblot analysis also showed decreased ABCF1 expression when BMDMs were treated with TNF-a and IL-1b, whereas increased ABCF1 expression was observed when BMDMs were treated with IL-10 and IFN-b ( Figure S1E ). ABCF1 expression correlated with cytokine production after peptidoglycan, CpG DNA, Poly I:C, and LPS stimulation ( Figure 1B, S1A ). This collectively suggests that ABCF1 expression positively regulates TRIF-dependent anti-inflammatory cytokine and IFN-b production by polarizing macrophages to an M2 phenotype, whereas the loss of ABCF1 phenocopies MyD88 signaling and leads to pro-inflammatory cytokine production by polarizing macrophages to an M1 phenotype.
ABCF1 Is a Class IV E2 Ubiquitin-Conjugating Enzyme
A screen of Abcf1 siRNA-treated and LPS-stimulated BMDMs identified the regulation of RING tripartite motif (TRIM) E3 ligases ( Figure 1E ). Previous studies have shown the involvement of certain TRIM E3s in TLR4 signaling (Kawai and Akira, 2011) and regulation and manipulation of these E3 ligases by E2 ubiquitin-conjugating enzymes (Ye and Rape, 2009) . We therefore hypothesized the possibility of ABCF1 being an E2 Ub-conjugating enzyme, despite the fact that, to date, no E2 ubiquitinconjugating activity has been reported in the ABC protein family.
We aligned the protein sequence of mouse ABCF1 with sequences of known mouse E2 enzymes using the CLUSTALW server. From this analysis, we identified regions in ABCF1 that are highly conserved within the Ub-conjugating catalytic (UBC) domain of E2s and are critical for their ubiquitination activity. We also identified a cysteine residue at position 647 that perfectly aligns with all the other known E2s in its active site (Figure 2A ). Because the secondary structure of ABCF1 has not been experimentally determined, we predicted the secondary structure of ABCF1 in silico using the homology modeling tools, YASPIN and APSSP server.
Although the core E2 topology is retained across the UBC domain and the critical catalytic cysteine is shared by all the E2s however, many structural variations have been observed in several members that deviate from the established structure of an E2 active site, an observation that is not uncommon among E2 enzymes. In agreement with other E2s, our homology modeling indicated that ABCF1 contains characteristic b-mean- ders in its UBC domain followed by a C-terminal active site b-hairpin flaplike structure (hereafter called ''flap'') ( Figure 2A ) (Burroughs et al., 2008) . ABCF1 also possesses a well-conserved cysteine residue embedded in the C-terminal region of the flap; as also seen in UBC13 and ATG10 E2s (Wu et al., 2003) . In accordance with previous studies, we also observed a conversed asparagine in the flap region ( Figure 2A ) (here after termed ''flap asparagine''), found in close proximity (7-15 residues) of the conserved cysteine, which has previously been implicated in stabilizing the oxyanion hole in the active site of the enzyme (Burroughs et al., 2008) . Like UBE2W, ABCF1 also contains the flap asparagine, but this asparagine is not as well conserved in other E2s. A conserved flap histidine upstream of the flap asparagine is also present in the E2 active site, and these polar residues have been known to come in contact with the catalytic cysteine and promote Ub binding (Burroughs et al., 2008) . However, in ABCF1, the presence of other polar residues (arginine, aspartate, and asparagine) in the active site and the histidine upstream of the flap region might assist in Ub binding. Alternatively, studies have suggested that both the flag asparagine and histidine residues are only conserved in a small number of families, likely because of differences in target E3 protein recognition (Burroughs et al., 2008 ). This appears to be the case for ATG10, which lacks both the flap asparagine and histidine residues (Figure 2A) (Burroughs et al., 2008) .
The presence of hydrophobic residues in the E2 flap region is thought to lower the pKa of the active site and mediate E2-E3 binding (Capili and Lima, 2007) . ABCF1 was found to contain the greatest number of hydrophobic residues (amounting to ten) among all the E2s shown in Figure 2A . In theory, this would lower the active site pKa and facilitate target lysine deprotonation. ABCF1 also contains a highly-conserved proline residue, which sits upstream of the flap region and tethers the flap to the b-meander and helps in stabilizing the entire structure (Burroughs et al., 2008) .
To experimentally validate our in silico analysis, we performed in vitro ubiquitination assays to investigate ABCF1 enzymatic activity, both in the presence and absence of an E1 Ub-activating enzyme (UBA1) and cofactors (Mg 2+ and ATP). An increase in the apparent molecular weight of ABCF1 was observed when recombinant ABCF1, UBA1, and Ub proteins were incubated in the presence of cofactors ( Figure 2B ). The Ub attachment to E2s occurs via thioester linkages and is DTT sensitive, and the observed protein band was lost when samples were treated with DTT. This suggests that a thioester bond was formed between ABCF1 and Ub in the presence of E1 and necessary cofactors, and the increase in apparent molecular weight was consistent with the addition of Ub to the ABCF1 catalytic cysteine.
To confirm that the conserved cysteine at position 647 in the ABCF1 sequence is the catalytic cysteine that mediates the E2 function, we performed in vitro ubiquitination assays with Abcf1 WT and Abcf1 C647S protein constructs. Again, a shift in the apparent molecular weight of ABCF1 was observed when Abcf1 WT construct was used in the assay. Importantly, no such shift was observed with Abcf1 C647S construct, indicating a critical role for this conserved cysteine in the ubiquitination reaction ( Figure 2C ).
We also confirmed our hypothesis by performing an in vitro ubiquitination assay with fluorescently-labeled antibodies. The Abcf1 WT+E1+Ub lane shows that ABCF1 and ubiquitin merge and display a yellow color, signifying binding of ABCF1 and ubiquitin proteins, which give rise to a second higher protein size band ( Figure 2D ). Earlier studies have suggested the categorization of E2 enzymes into four classes based on the presence of Nand/or C-terminal extensions to the UBC domain (van Wijk and Timmers, 2010). ABCF1's conserved cysteine is at position 647 and, based on bioinformatics analysis, its UBC domain ends soon after position 647. Considering ABCF1 is 840 amino acids long, it must contain considerable N-and C-terminal extensions, which is characteristic of class IV E2s. Taken together, these data strongly implicate that ABCF1 is a class IV E2 ubiquitin-conjugating enzyme with a conserved catalytic cysteine at position 647.
ABCF1 Is Necessary for TLR4 Endocytosis
Once activated, TLR4 is internalized into endosomes, decreasing its expression on the cell surface (Kagan et al., 2008) . This phenomenon activates TRIF-mediated signaling, which leads to the dimerization and nuclear translocation of IRF3, and subsequent production of IFN-I (Figure 1 ) (Kagan et al., 2008) . As a readout of TLR4 endocytosis, we monitored the loss of TLR4 surface expression over time in BMDMs stimulated with various concentrations of LPS (Zanoni et al., 2011) . Flow cytometry analysis of cell-surface TLR4 showed that endocytosis could be observed within 30 min of stimulation and at LPS concentrations as low as 10 ng/mL (Figures S2A and S2B) . Using siRNA to silence ABCF1 in BMDMs, with or without LPS stimulation, resulted in a clear increase in cell-surface TLR4 ( Figures S2C and S2D ). The cell-surface TLR4, in this case, were significantly reduced when cells were stimulated with LPS, as compared to without. After LPS stimulation, TLR4 tends to endocytose in the endosome, but the loss of ABCF1 favors it to be expressed on cell-surface instead ( Figure S2D ). Thus both the Abcf1 siRNA-treated and LPS-stimulated BMDMs do display increased cell-surface TLR4 when compared with their respective controls, but the expression was considerably reduced when compared to their non-LPS treated counterparts ( Figure S2D ).
This disparity in cell-surface TLR4 elicited a clear elevation in pro-inflammatory cytokines, NF-kB and MAPK expression in Abcf1 siRNA treated BMDMs in the absence of LPS, when compared with the scrambled controls and LPS treated counterparts. Additionally, both the Abcf1 siRNA-and LPS-stimulated BMDMs did display increased pro-inflammatory cytokines, NF-kB, and MAPK expression, when compared to the scrambled and LPS treated BMDMs, but to a lesser extent, due to comparative reduction of cell-surface TLR4 on these cells than their non-LPS-stimulated counterparts (Figure 1, S1 ). Conversely, considerably reduced cell-surface TLR4 was detected in BMDMs engineered to overexpress WT ABCF1. This phenomenon was reversed when BMDMs were modified to overexpress the C647S mutant form of ABCF1, suggesting a potential role for ABCF1-mediated ubiquitination in TLR4 endocytosis ( Figures S2C and S2D ).
We also confirmed these results in vivo using Het mice injected with LPS. At every time point examined, CD11b + and F4/80 + splenic macrophages exhibited a considerable increase in TLR4 surface staining than their WT counterparts ( Figure S2E ).
ABCF1 Regulates the Transition from MyD88-to TRIF-Dependent Signaling
The regulation of the shift from MyD88-to TRIF-signaling during TLR4 endocytosis is still an open question in immunology. siRNA silencing of ABCF1 resulted in a modest increase in the p-TAK1 (a MyD88-signaling associated kinase) in BMDMs stimulated with LPS ( Figure S1C ). By contrast, phosphorylation of the TRIF-signaling associated kinase, TBK1, was greatly attenuated ( Figure S1C ). We also observed reduced expression of A20 (a negative regulator of the MyD88-signaling) in Abcf1 siRNAtreated BMDMs both with and without LPS stimulation. Furthermore, several MyD88-signaling associated kinases like MAPK kinases and MAPK-specific transcription factors followed the same trend of phosphorylation as p-TAK1, while TRIF-dependent production of interferon stimulated genes (ISG)-specific transcription factors followed the same trend of expression as A20 ( Figures 3A and 3B ). Overexpressing ABCF1 in BMDMs corroborated these results, displaying changes in expression of p-TAK1, A20, p-TBK1, and p-IRF3 that were indicative of TRIF-dependent signaling ( Figure S1D ). These results support the hypothesis that ABCF1 seems to negatively regulate MyD88-dependent signaling and positively regulates TRIFdependent signaling in macrophages responding to LPS.
ABCF1 Is Targeted for K48-and K63-Polyubiquitination by cIAP1/2 and TRAF6 Thus far, our data demonstrates that ABCF1 mediates TLR4 endocytosis and facilitates the shift toward the TRIF-IFN-I signaling axis. Because the regulation of TLR4 signaling is known to involve the polyubiquitination of key effectors, including TRAF3, TRAF6, and cIAP1/2 (Kawai and Akira, 2011, Tseng et al., 2010) , we hypothesized that ABCF1 itself might be regulated by polyubiquitination. We observed increased expression of K48-polyubiquitinated ABCF1 when BMDMs were stimulated with LPS (10 ng/mL) for 5, 10, and 20 min ( Figure 3C ), suggesting that ABCF1 was bound for degradation. We also observed that polyubiquitination of ABCF1 shifted to K63 linkages after 30 min of LPS stimulation ( Figure 3C, D) . This suggested that ABCF1 appears to be the target of both K48-and K63-polyubiquitination by other proteins. The timing of the K48-and K63-linkages after LPS stimulation coincided, respectively, with early-phase MyD88-dependent signaling via MAPK and NF-kB pathways at earlier time points, and ABCF1's positive regulation of TLR4 endocytosis and late-phase TRIF-dependent signaling at 30 min (Figures 1, S1 , S2). We sought to better understand the regulation of ABCF1 polyubiquitination and the mechanism of the switch from K48 to K63 linkages. cIAP1/2 is an E3 ubiquitin ligase that mediates the formation of K48 linkages on TRAF3 during early-phase TLR4 signaling, a process that inhibits the transition to late-phase TRIF signaling (H€ acker et al., 2011 (H€ acker et al., , Tseng et al., 2010 . Therefore, we hypothesized that cIAP1/2 might also target ABCF1 for degradation in a similar fashion. Upon stimulation of BMDMs with LPS for 30 min, polyubiquitinated forms of ABCF1 were found to be predominantly K63-linked ( Figures 3C, 3D, 4A ). These linkages were even more prevalent when cells were treated with Smac-Mimetic (SM), a small molecule that rapidly triggers cIAP1/2 degradation, in presence of LPS for 30 min ( Figure 4A ). Inhibiting TLR4 endocytosis with the dynamin inhibitor, Dynasore, greatly reduced the prevalence of K63 linkages and extensively upregulated K48 linkages upon LPS stimulation at 30 min. At LPS treatment for 10 min, ABCF1 linkages were K48-polyubiquitinated ( Figures 3C, 3D,  4A ), but SM treatment led to K63-polyubiquitination of ABCF1 instead ( Figure 4A) . Whereas, at LPS treatment for 30 min, cIAP1/2 undergoes self-degradation (Tseng et al., 2010) (Figure 4A) , and SM treatment further enhances the K63-polyubiquitination of ABCF1 ( Figure 4A ). Additionally, Dynasore treatment alone also led to K48-polyubiquitination of ABCF1. Whereas, treatment with both SM and Dynasore abolished K48-and K63-polyubiquitination of ABCF1 altogether ( Figure 4A ) and (Tseng et al., 2010) . These results collectively suggest that cIAP1/2 targets ABCF1 for K48-polyubiquitination upon LPS-TLR4 engagement and this step occurs prior to TLR4 endocytosis.
Consistent with this, we observed that siRNA silencing of cIAP1/2 increased ABCF1 expression and reduced p-TAK1 in BMDMs stimulated with LPS for 30 min ( Figure S3A ). The observed reduction of p-TAK1 is in line with previous findings that cIAP1/2 is essential for TAK1-mediated MAPK and NF-kB signaling (Tseng et al., 2010) and our data of ABCF1's negative regulation of TAK1-mediated MAPK and NF-kB signaling (Figures 1 and S1 ).
TRAF6 is an E3 ligase that mediates the K63-polyubiquitination of both cIAP1/2 and TRIF (Sasai et al., 2010) . We asked whether TRAF6 might also be necessary for the observed formation of K63-polyubiquitin chains on ABCF1 during late-phase (TRIF-dependent) TLR4 signaling. TRAF6 was found to co-immunoprecipitate with ABCF1 in BMDMs stimulated with LPS for 30 min, suggesting a potential role for TRAF6 in ABCF1-mediated signaling (Figure S3B) . Next, we performed an in vitro ubiquitination assay where various constructs were co-transfected in BMDMs. After 30 min of LPS stimulation, overexpression of TRAF6 was able to strongly induce K63-polyubiquitination of ABCF1, while no K48 linkages were ever detected ( Figure 4B ). These findings indicate that early-phase TLR4 signaling targets ABCF1 for cIAP1/2-mediated K48-poly- Figure S3 .
ubiquitination, while ABCF1 is K63-polyubiquitinated during late-phase signaling by TRAF6.
ABCF1 Associates with and
Mediates the K63-Polyubiquitination of SYK and TRAF3 Our study that ABCF1 is an E2-Ub conjugating enzyme prompted us to explore whether this activity plays a role in ABCF1's positive regulation of TRIFdependent signaling. Co-immunoprecipitation studies in LPS-stimulated BMDMs revealed that while ABCF1 associates with SYK ( Figures S3B and S3C ), no interaction with PLCg2 was observed (data not shown). Further siRNA silencing of ABCF1 was found to decrease p-SYK and p-PLCg2 expression in LPS-stimulated BMDMs ( Figure S3E ). This suggests a mechanism for the previously observed TLR4 endocytosis defect when ABCF1 is silenced. To investigate whether ABCF1's E2 activity regulates SYK, we analyzed the formation of polyubiquitinated species of SYK in BMDMs co-transfected with various constructs. In the absence of LPS stimulation, polyubiquitination of SYK was never detected ( Figure 4C ). After 30 min of LPS stimulation, K63-polyubiquitination of SYK was detected in BMDMs overexpressing Abcf1 WT, Ub-K63, and Syk plasmids, whereas no K48-polyubiquitin chains were observed. Notably, the formation of these K63 linkages was inhibited when Abcf1 WT was substituted with the Abcf1 C647S mutant plasmid, suggesting that the conserved cysteine is necessary for ubiquitin transfer and critical for the E2 activity of ABCF1.
Previous studies have shown that SYK associates with TRAF6 (Lin et al., 2013) and our data showed that TRAF6 and SYK associate with ABCF1 during TLR4 endocytosis ( Figures S3B and  S3C) , possibly implying the formation of a TRAF6-ABCF1-SYK complex. This suggests that during late-phase TLR4 signaling, TRAF6 binds with both target protein, SYK, and E2 enzyme, ABCF1, and perhaps acts like a scaffold to aid in the K63-polyubiquitination of SYK by ABCF1 in an E3-RING domain-like fashion.
Polyubiquitination of TRAF3 is known to be an essential checkpoint in TLR4-TRIF pathway, and non-canonical self-polyubiquitination of TRAF3 is thought to be the key driver for this regulation (H€ acker et al., 2011 (H€ acker et al., , Tseng et al., 2010 . In our coimmunoprecipitation studies, we observed an interaction between ABCF1 and TRAF3 ( Figures S3B and S3D ). It is possible that this interaction is indicative of a scenario where the E2 ubiquitin-conjugating enzyme (ABCF1) interacts with an unknown E3 ligase to facilitate the transfer of its ubiquitin moiety to a target substrate (TRAF3) instead.
In order to examine whether ABCF1 targets TRAF3 for polyubiquitination Abcf1, Traf3, and ubiquitin expression constructs were co-transfected in BMDMs. Robust K63-polyubiquitination of TRAF3 was only observed when BMDMs overexpressed Abcf1 WT, Ub-K63, and Traf3 plasmids in the presence of LPS ( Figure 5A ). This polyubiquitination reaction required K63 linkages, as negligible amounts of K48 linkages were detected under all other conditions tested. Importantly, K63-polyubiquitination of TRAF3 was completely abolished when the Abcf1 WT plasmid was replaced with the C647S mutant plasmid, indicating a critical role for the conserved catalytic cysteine in this reaction ( Figure 5A ). These results collectively suggest that upon LPS stimulation, ABCF1 targets TRAF3 for K63-polyubiquitination in an E3-RING domain like fashion. As no interaction was observed between TRAF3 and TRAF6 (data not shown), the identity of the E3 ligase that aids in this RING domain-mediated transfer is still unknown.
Previous studies have shown that TRAF3 polyubiquitination is dependent on its interaction with TRIF (H€ acker et al., 2011 (H€ acker et al., , Tseng et al., 2010 . To examine whether the interaction between ABCF1 and TRAF3 depends on TRIF, we treated BMDMs with Trif siRNA in the presence or absence of LPS and immunoprecipitated ABCF1. A strong interaction between ABCF1 and TRAF3 was observed after LPS stimulation, and siRNA silencing of TRIF did not affect this association ( Figure 5B ). Treating BMDMs with both Trif siRNA and LPS led to decreased p-TBK1, confirming that TRIF-dependent TRAF3 ubiquitination is important for downstream signaling ( Figure 5B ) (H€ acker et al., 2011 (H€ acker et al., , Tseng et al., 2010 . Therefore, it appears that although TRIF is not necessary for ABCF1 and TRAF3 association, perhaps ABCF1 first interacts with TRAF3 and then this complex recruits TRIF (Figure S3B ), facilitating the ABCF1-mediated K63-polyubiquitination of TRAF3 in a TRIF-dependent manner.
ABCF1 Targets TRAF3 for K63-Polyubiquitination and Controls the IFN-b-SIRT1 Dependent Sepsis
Immunotherapy, Thereby Protecting against Sepsis Induced Mortality During sepsis, the transition from SIRS phase ET phase is not well understood. Macrophages are thought to be the main producers of inflammatory cytokines during both these phases (Schmauder-Chock et al., 1994 , Ge et al., 1997 , and their plasticity has been shown to mediate the transition of the disease to the TRIF-dependent ET phase (Biswas et al., 2007, Biswas and Lopez-Collazo, 2009 ). Because ABCF1 governs the switch from MyD88 to TRIF signaling, we hypothesize that the reduced expression of ABCF1 in Het mice would impair their ability to undergo this transition during gram-negative sepsis.
As a model for sepsis, we injected WT and Het mice with endotoxin (LPS) as described in the STAR Methods. Pretreatment of WT mice with endotoxin (ETT-WT) induced endotoxin tolerance and resulted in a serum cytokine profile indicative of the ET phase of sepsis. Specifically, we observed a 30-to 50-fold reduced expression of pro-inflammatory cytokines, 10-to 20-fold reduced expression of T cell attracting chemokines (CXCL9 and CXCL10), and 60-fold reduced expression in T cell proliferative cytokine (IL-1a). ETT-WT mice also concomitantly displayed increased expression of anti-inflammatory cytokines and IFN-b, again recapitulating the ET phase of sepsis. In contrast to this, the ETT-Het mice exhibited a 40-to 60-fold elevation in pro-inflammatory cytokines when compared with ETT-WT mice ( Figure 6A ) and a 20-to 30-fold reduced expression of anti-inflammatory cytokines. The non-endotoxin treated (NETT)-Het mice also exhibited a proinflammatory response but to a lesser extent than their ETT-Het counterparts.
The serum cytokine profile of ETT-Het mice suggested these mice were unable to transition to the ET phase of sepsis and remained permanently in the hyperinflammatory SIRS phase of the disease, thus exhibiting a phenotype of cytokine storm. The polarized serum cytokine profiles of the ETT-WT and ETT-Het mice were manifested in different survival rates for these mice. Only 55% of ETT-Het mice survived for 8 hours after the second (high-dose LPS) injection, and there were no survivors after 16 hours (Figure 6B ). Yet, ETT-WT mice, had a 90% survival rate by the end of the 96-hour study. By contrast, NETT-WT mice had a 60% survival rate, whereas only 10% of NETT-Het mice survived by the end of 96 hours ( Figure 6B) .
In order to examine innate immune signaling pathways in greater detail, we analyzed the expression of key kinases and transcription factors signaling in post septic ex vivo cultured splenic macrophages from these mice as previously described (den Haan and Kraal, 2012, Deng et al., 2004) . Splenic macrophages from ETT-Het mice displayed increased expression of p-TAK1 and reduced expression of A20 and p-IRF3 when compared to ETT-WT ( Figure S4A ). Like SPDMs, post septic ex vivo cultured BMDMs have also been shown to regulate sepsis immunotherapy through bone-marrow-hematopoiesisdependent changes (Muthu et al., 2008) . Bone marrow is the center for hematopoiesis, which gives rise to both circulatory (Sunderkö tter et al., 2004) and tissue-resident macrophages (Davies et al., 2013) . It takes 2-5 days for macrophage development from bone marrow progenitors before they transit into circulation. Once in circulation, the immune response elicited by macrophages in peripheral blood around day 2-3 and beyond, are most likely to be a reflection of changes emerging from bone marrow monocytes at an earlier time point (Muthu et al., 2008 , Sunderkö tter et al., 2004 . The ETT-Het mice died within 16 hours of the second LPS injection, as compared to the ETT-WT mice, which showed 90% survival even after 96 hours (Figure 6B) , suggesting that the anomalies seen in these mice were due to changes in the bone marrow and were perhaps ABCF1-dependent. Therefore, we decided to study the role of BMDMs and bone marrow transplant in sepsis-induced inflammation and mortality. Like splenic macrophages, BMDMs from ETT-Het mice also showed an increase in p-TAK1 and decrease in A20 expression, when compared with ETT-WT mice (Figure 6C) . The predominance of MyD88-dependent signaling in ETT-Het BMDMs and TRIF-dependent signaling in ETT-WT BMDMs mimicked the activity of these signaling pathways during the SIRS and ET phases of sepsis, respectively.
Previous studies have also shown modulation of SIRS phase of sepsis and sepsis-induced mortality by bone marrow transplant (Lorigados et al., 2018 , Huang et al., 2017 . We hypothesized that ABCF1 deficiency in bone-marrow-derived haemopoietic cells was responsible for this increase in susceptibility to developing sepsis. Therefore, we performed a bone-marrow transplantation (BMT) experiment where we reciprocally transferred Het bone marrow to WT animals and WT bone marrow to Het animals and looked for sepsis-induced pathogenesis. The BMT was performed as described in STAR Methods, and the repopulation of bone marrow was examined ( Figure S5A ) and cytokine profiles and mortality were monitored. Even without any endotoxin treatment, Het mice produced increased pro-inflammatory cytokine production when compared to their WT littermates ( Figure S5B ). After endotoxin treatment, WT mice that received the Het bone marrow (BMT-ETT-Het) showed the same phenotype of cytokine storm as of ETT-Het mice (Figure S5B ). These mice were more susceptible than regular WT mice to the endotoxin infection and died within 14 hours of second (high dose LPS) injection ( Figure S5C ). This timeline was similar to the ETT-Het mice, which died at 16 hours ( Figure 6B ). Whereas Het mice that received the WT bone marrow (BMT-ETT-WT) showed the same phenotype of endotoxin tolerance as of ETT-WT mice and showed 100% survival, even after the end of 96 hours ( Figure S5C ). These data support the conclusion that ABCF1 genetic deficiency in the hematopoietic lineage transfers susceptibility to endotoxin-induced sepsis, indicating that ABCF1 is a key negative regulator of pathogenesis in sepsis.
Our earlier data suggests that ABCF1 is essential for the shift from MyD88-to TRIF-dependent signaling and also for TRAF3-mediated IRF3-dependent IFN-I production ( Figure 5 ). Therefore, in order to investigate whether the immunotherapeutic effect of IFNb during sepsis depends on the activity of ABCF1, we examined the possibility that ABCF1 targets TRAF3 for ubiquitination during sepsis. IB analysis of ETT-Het BMDMs revealed increased K48-polyubiquitination of TRAF3, suggesting these proteins were destined for proteasomal degradation, hence activating the MyD88 pathway characteristic of SIRS ( Figure 6D ). By contrast, increased K63-polyubiquitination of TRAF3 was observed in ETT-WT BMDMs, suggesting activation of the TRIF-IFN-I pathway characteristic of the ET phase ( Figure 6D ). Elevated p-IRF3 (Figure 6C ), dimerized IRF3 ( Figure 6E) , and IFN-b ( Figure 6A ) expression were also observed in ETT-WT BMDMs, whereas no IRF3 dimerization and a 30-to 40-fold reduction in IFNb was seen in ETT-Het BMDMs. These results support the hypothesis that ABCF1 seems to be necessary for TRAF3 activation (K63-polyubiquitination) and subsequent IRF3 phosphorylation and dimerization, ultimately leading to the production of IFN-b, a crucially protective cytokine in LPSinduced sepsis.
The protective effect of IFN-b during sepsis is thought to depend on its positive regulation of the JAK-STAT pathway and, consequently, SIRT1 production (Yoo et al., 2014) . We observed a 50-to 70-fold reduced expression of p-STAT transcription factors ( Figure 7B ) and an absence of SIRT1 in ETTHet BMDMs ( Figure 6C ). Moreover, increased p-NF-kB p65 was observed in BMDMs of ETT-Het mice ( Figure 7A ), demonstrating that even a single allele of ABCF1 was insufficient to maintain SIRT1 expression, which thereby regulates inflammation through NF-kB p65. Thus, ABCF1 appears to control the switch from MyD88-to TRIF-dependent signaling during the SIRS-to-ET transition in sepsis, facilitating IFN-b-dependent production of SIRT1.
Physiologically, the expression of ABCF1 in BMDMs from the sepsis-induced mice correlated with their mortality. BMDMs from ETT-Het mice that died 8 and 16 hours after high-dose LPS injection expressed negligible amounts of ABCF1 and p-IRF3 ( Figure S4B ). BMDMs from NETT-Het mice exhibited a 90-fold reduced ABCF1 expression and an 85-fold reduced p-IRF3 expression at 32 and 40 hours post high-dose LPS injection, respectively, when compared with untreated WT mice. Additionally, the mortality of NETT-WT mice also correlated with reduced ABCF1 and p-IRF3 expression ( Figure S4B ). The ETT-WT group had a 90-fold increased survival rate at the end of the 96-hour study, with only one mouse in the group dying (at 72 hours). BMDMs from this mouse had a 35-fold increase in ABCF1 and 65-fold increase in p-IRF3, when compared with untreated WT BMDMs, but had to be euthanized as it displayed more than 20% weight loss (UBC-CCAC, STAR Methods). By contrast, we observed a 47-fold elevation in ABCF1 and 72-fold elevation in p-IRF3 in BMDMs from an ETT-WT mouse that survived the 96-hour study, when compared with the untreated WT group ( Figure S4B) . Therefore, ABCF1 expression correlated with both p-IRF3 and mouse survival after highdose LPS injection and rescued the mice from SIRS-mediated mortality.
BMDMs from ETT-Het Mice Undergo Extensive Pyroptosis While caspase-3-mediated apoptosis of immune cells is the leading cause of secondary infection during the ET phase of sepsis (Hotchkiss et al., 2003) , caspase-1-dependent pyroptosis is the primary cause of immune cell death during the SIRS phase of sepsis (Jorgensen and Miao, 2015) . Serum cytokines from ETT-Het mice showed a phenotype consistent with cytokine storm, with elevated expression of IL-1b, HMGB1, IL-6, and TNF-a ( Figure 6A ). BMDMs from ETT-Het mice also showed elevated expression of NLRP3, ASC, and cleaved caspase-1, as well as decreased cleaved caspase-3 when compared with ETT-WT BMDMs ( Figure 6C ). In addition, we observed reduced phosphorylation of apoptosis-associated kinases like AKT in BMDMs from ETT-Het mice ( Figure S4C) . A similar trend of pyroptosis was also observed in LPS-stimulated BMDMs treated with Abcf1-specific siRNA ( Figure S4D ). These results indicate that ABCF1 plays an important role in transitioning BMDMs from pyroptotic to apoptotic cell death pathways during sepsis.
ABCF1 Haplo-Insufficient Mice Develop Renal Circulatory Failure in the SIRS Phase Increased expression of circulating pro-inflammatory cytokines is associated with multiple organ failure on the background of persistent circulatory failure (Varpula et al., 2005) . During SIRS, endotoxemia leads to the upregulation of TNF-a, which alters renal microcirculation and hemodynamics, and leads to acute kidney injury (Ramseyer and Garvin, 2013, Doi, 2016) , which ultimately leads to death (Harty, 2014) .
ETT-Het mice injected with a high dose of LPS were unable to leave the SIRS phase and showed a 50-to 60-fold upregulation of pro-inflammatory cytokines ( Figure 6A ). This was also confirmed by measuring serum Procalcitonin expression. ETT-Het mice displayed significantly increased expression of serum procalcitonin when compared with their WT counterparts ( Figure 7C ). Histological analysis of these mice revealed widespread dilation and congestion of small vessels in their kidneys ( Figure S4E ). In addition, these images clearly depict the ''sludging'' effect of red blood cells (shown by black arrows) being compacted together in dilated or congested vessels. This form of vasculature dilation and congestion on a systemic scale results in a critical drop in blood pressure, causing insufficient blood and oxygen to reach critical central organs, including the brain and heart. The kidneys of the ETT-Het mice exhibited a greater sludging and vascular dilation compared to ETT-WT mice, suggesting increased congestion of blood vessels and thus contributing to severe hypotension. ETT-Het mice also displayed an increase in serum L-Lactate and serum Creatinine levels ( Figures 7D and 7E ). This suggests that the ETT-Het mice died due to hypertension induced kidney injury due to increased procalcitonin or cytokine storm. Moreover, the bone-marrow-transplanted mice also displayed the same phenotype, where the BMT-ETT-Het mice showed significantly increased serum procalcitonin, L-Lactate and Creatinine ( Figures S5D-S5F ) when compared with their WT counterparts. Collectively, these data support our conclusion that survival during SIRS phase is ABCF1 dependent.
DISCUSSION
Sepsis is a bi-phasic inflammatory disease, with the molecular mechanisms underlying its immunomodulation and the shift between its SIRS and ET phases still being established. We sought to identify innate immune regulators of LPS-TLR4 signaling and discovered that ABCF1 acts as a molecular switch that mediates the transition from a MyD88-associated cytokine storm phenotype (SIRS) to a TRIF-associated endotoxin tolerant phenotype (ET) during gram-negative sepsis.
Here, we have reported the discovery of an E2 ubiquitin-conjugating enzyme, ABCF1, which controls this transition in macrophages. ABCF1-deficient macrophages were defective in TLR4 endocytosis and were unable to transition from MyD88-to TRIF-dependent signaling in response to LPS stimulation. Consequently, they produced predominantly NF-kB-and MAPK-specific pro-inflammatory cytokines, resulting in an M1-like phenotype. Furthermore, during endotoxin-induced sepsis, Het mice were unable to transition from the SIRS phase to the ET phase, displaying exaggerated expression of MyD88-associated pro-inflammatory cytokines in the serum, activated pyroptotic cell death pathways, and finally exhibiting renal circulatory failure, which resulted in premature death. These data support the conclusion that physiologically, ABCF1 expression enhances TRIF-dependent anti-inflammatory cytokine and IFN-b production by polarizing macrophages to an M2 phenotype. Inversely, the loss of ABCF1 phenocopies MyD88 signaling and leads to pro-inflammatory cytokine production by polarizing macrophages to an M1 phenotype.
During TLR4 signaling, ABCF1 was able to target SYK for K63-polyubiquitination and also positively regulated SYK and PLCg2 phosphorylation, which subsequently mediates TLR4 endocytosis. Further studies need to be conducted to determine whether this polyubiquitination of SYK is important for its phosphorylation (or vice versa) and subsequent mediation of TLR4 endocytosis. This observation raises the possibility that ABCF1 could also regulate the SYK-mediated endocytosis of other receptors (Dectin-1, FcgRs). As IFN-I is known to be protective during certain viral infections and counteracts cancer progression, the ABCF1-IFN-I signaling axis may be an attractive target for therapeutic intervention. LPS endotoxin is a potent trigger of gram-negative sepsis. By performing endotoxin-treatment of WT and Het mice following reciprocal bonemarrow transplantation, we established that susceptibility to sepsis is dependent upon the genotype of the hemopoietic compartment and increased resistance to sepsis is dependent on the expression of ABCF1 in the hemopoietic compartment. Thus, ABCF1 normally functions as a dampener of lethal septic shock.
Previous studies have mapped ABCF1 as a risk factor gene for rheumatoid arthritis and autoimmune pancreatitis (Ota et al., 2007 , Richard et al., 1998 . Additionally, recent genome-wide association studies have also associated ABCF1 with the risk of gout (Dong et al., 2017 ) and Crohn's disease (Hindorff et al., 2009) . The dysregulation of innate immune responses is thought to be a key factor for the prognosis of these immunological disorders, and current research is focusing on modulating cytokine secretion by macrophages. Given that ABCF1 negatively regulates MyD88-dependent TLR2 and TLR9 signaling, positively regulates TRIF-dependent TLR3 signaling, and is essential for the MyD88-to-TRIF transition during TLR4 signaling, it is likely that ABCF1 regulates innate immune responses, macrophage polarization, and cytokine production in these autoimmune disorders. Further work is required to understand the precise role of ABCF1 in the regulation of these diseases.
For several decades, research has focused on discovering TLR4 inhibitors that control pathogenesis during sepsis (Wittebole et al., 2010) . Here, we describe a keystone regulator that could control the understudied shift from the SIRS to ET phase of sepsis in patients, thereby modulating sepsis mortality. Thus, ABCF1 might be a potential target for pharmacological drug development to protect against sepsis. Further work is needed to exploit this target to modify patient outcomes in various diseases.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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MICE AND CELLS
Bone marrow cells were isolated from femur and tibia of C57BL/6 mice and were matured into macrophages as described (Trouplin et al., 2013) . Briefly, mouse bone marrow was obtained by flushing the tibia and femur of a C57BL/6 mouse with Roswell Park Memorial Institute medium (RPMI) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS). Bone marrow cells were cultured in 10 mL of RPMI supplemented with 10% FBS, glutamine, and 30% L929 cell supernatant containing macrophage colony-stimulating factor at an initial density of 10 6 cells/mL in 100-mm Petri dishes at 37 C in humidified 5% CO 2 for 6 days. Cells were harvested with cold PBS, washed, resuspended in RPMI supplemented with 10% FBS, and used at a density of 2X10 6 cells/mL. different antibodies printed in duplicates provided with Proteome Profiler Human Phospho-Kinase Array Kit (R&D Systems; ARY003B) and chemiluminescence intensities were measured. This kit can also be used for mouse samples and has previously been tested by (O'Hara and Garcea, 2016, Chen et al., 2010) . Treatments and incubations were done as indicated in the respective figure legends and phospho-kinase analysis was performed according to manufacturer's instructions. Phospho-kinase expression are depicted as fold change and represented as heatmaps as described below.
IRF3 DIMERIZATION ASSAY
2X10 7 cells were lysed in a buffer containing 50 mM Tris, pH 8.0, 1% NP40, 150 mM NaCl, 1 mM PMSF and 20 mg/mL of aprotinin, and supplemented with native PAGE sample buffer (125 mM Tris, pH 6.8, and 30% glycerol). The samples were separated by native PAGE and analyzed by immunoblotting.
CYTOPLASMIC AND NUCLEAR FRACTIONATION
Bone marrow macrophages were stimulated with indicated treatments and cytoplasmic and nuclear fractionation was performed with NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific; 78833) according to manufacturer's instructions.
IN VITRO UBIQUITINATION ASSAY
Abcf1 WT and Abcf1 C647S expression plasmids were overexpressed in macrophages as described above. Before overexpressing Abcf1 C647S expression plasmid, cells were treated with Abcf1 siRNA, as described above to eliminate endogenous ABCF1 expression. Abcf1 siRNA treated cells were washed with cold PBS twice and then Abcf1 C647S expression plasmid was overexpressed. Cell lysates were prepared and subjected to co-immunoprecipitation with anti ABCF1 antibody. Extent of overexpression and coimmunoprecipitation was checked by western blot. Ubiquitination assay was performed on immunoprecipitated samples with Ubiquitylation Assay Kit (abcam; ab139467) according to manufacturer's instructions. Samples were run on a polyacrylamide gel and blotted with anti ABCF1 and anti UB antibodies.
STATISTICAL ANALYSIS
The data are presented as the mean ± SD. The means were compared by paired or unpaired Student's t tests. P-values < 0.05 were considered significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Survival is presented as Kaplan-Meier curves and differences were assessed by the log-rank test in GraphPad prism software. Sample size for each experiment is indicated in the figure legend.
